Last updated: October 29, 2026
XALATAN, Pfizer’s latanoprost ophthalmic solution, was one of the largest glaucoma products before U.S. patent expiry. FDA approval came in 1996, and U.S. generic entry began in 2011 after loss of market exclusivity. The product’s commercial profile then shifted from branded growth to rapid price erosion, generic substitution, and limited strategic value for Pfizer.
XALATAN’s core patent estate is expired. Its principal U.S. compound and formulation protection ended in 2011, while related method-of-use protection extended into approximately 2012. No meaningful biosimilar risk applies because latanoprost is a synthetic small molecule, not a biologic. The principal ongoing commercial risks are generic substitution, reimbursement pressure, preservative-free competition, and migration to newer glaucoma therapies.
What is XALATAN and how does latanoprost work?
XALATAN is the brand name for latanoprost ophthalmic solution 0.005%. Pfizer markets it for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
Latanoprost is a prostaglandin F2alpha analogue. It is hydrolyzed in the cornea to an active acid that increases uveoscleral outflow of aqueous humor. The usual dosage is one drop in the affected eye once daily, generally in the evening. The labeled solution contains benzalkonium chloride as a preservative. [1]
| Product characteristic |
XALATAN |
| Active ingredient |
Latanoprost |
| Strength |
0.005% |
| Dosage form |
Ophthalmic solution |
| Initial U.S. approval |
1996 |
| FDA sponsor |
Pharmacia, later Pfizer |
| Primary indication |
Open-angle glaucoma and ocular hypertension |
| Pharmacologic class |
Prostaglandin analogue |
| Biologic status |
Small molecule |
| U.S. generic status |
Generic versions approved and marketed |
| Current patent position |
Core U.S. patents expired |
The product’s clinical value came from once-daily dosing, strong intraocular-pressure reduction, and a relatively simple administration profile compared with older beta blockers and carbonic anhydrase inhibitors.
When did XALATAN lose U.S. exclusivity?
XALATAN lost effective U.S. exclusivity in 2011 when generic manufacturers entered after expiry of its principal patent protection. The product had already reached maturity before that date, so the commercial impact was substantial.
XALATAN exclusivity timeline
| Event |
Date or period |
Commercial effect |
| U.S. approval |
1996 |
Start of branded commercialization |
| Early prostaglandin analogue adoption |
Late 1990s to 2000s |
Rapid growth in glaucoma treatment |
| Pfizer ownership following Pharmacia acquisition |
2003 |
Product integrated into Pfizer portfolio |
| Principal U.S. patent expiry |
Approximately 2011 |
Generic entry opportunity |
| Generic latanoprost launches |
2011 onward |
Rapid branded price and volume pressure |
| Method-of-use protection |
Approximately through 2012 for relevant patents |
Limited residual protection |
| Post-exclusivity period |
2012 onward |
Mature generic market |
The original U.S. patent estate included U.S. Patent No. 5,296,504, which covered latanoprost ophthalmic compositions and was associated with expiration in 2011. Related patents, including U.S. Patent No. 5,422,368, provided additional protection relevant to use or treatment and extended the protection period for certain claims into approximately 2012. Patent term details depend on the specific patent, terminal disclaimers, adjustments, and pediatric exclusivity. [2]
The practical market event was generic entry in 2011, not the later expiration of every residual claim. Once substitutable generic latanoprost became available, the branded product lost pricing power.
What patents protect XALATAN?
The principal XALATAN patents protected the active ingredient’s ophthalmic use and the composition used to deliver latanoprost.
Core patent categories
| Patent category |
Covered subject matter |
Current status |
| Composition patents |
Latanoprost ophthalmic solution and related compositions |
Expired |
| Method-of-use patents |
Reduction of intraocular pressure and glaucoma treatment |
Expired |
| Formulation patents |
Concentration, vehicle, stability, and preservative characteristics |
Expired or commercially superseded |
| Manufacturing patents |
Production or handling of latanoprost and ophthalmic formulations |
No material barrier to ordinary generic entry |
| Device or delivery claims |
Conventional eye-drop administration |
No meaningful exclusivity remaining |
The main patent weakness is age. Latanoprost was approved in the 1990s, and the relevant U.S. patent terms ended more than a decade ago. Patent protection in other jurisdictions also expired or lapsed as the applicable national terms ended.
A generic manufacturer did not need to reproduce Pfizer’s brand packaging or commercial strategy. It generally needed to demonstrate pharmaceutical equivalence and bioequivalence under the FDA abbreviated new drug application pathway.
What is the FDA and Orange Book status of XALATAN?
XALATAN is an FDA-approved prescription ophthalmic product listed in the FDA’s drug databases and associated with generic latanoprost products. Its core Orange Book patent listings no longer provide an effective barrier to ANDA approval because the relevant patents have expired.
The FDA-approved product is a sterile ophthalmic solution containing latanoprost 0.005%. Generic products are approved in the same strength and dosage form. The principal regulatory issue is pharmaceutical equivalence, including active ingredient, concentration, dosage form, route of administration, and quality controls.
Regulatory status
- FDA pathway for generic products: ANDA.
- Reference listed drug: XALATAN ophthalmic solution.
- Dosage form: sterile ophthalmic solution.
- Generic active ingredient: latanoprost.
- Biosimilar pathway: not applicable.
- Orange Book litigation significance: largely historical because the key patents have expired.
- Current regulatory barrier: manufacturing quality, sterility, stability, and bioequivalence.
XALATAN’s regulatory durability is therefore different from its patent durability. The product remains clinically relevant, but its brand-level regulatory exclusivity has ended.
Were there Paragraph IV challenges to XALATAN?
Generic latanoprost applicants had commercial incentives to challenge or design around the listed patents before expiry. Paragraph IV certifications are the standard Hatch-Waxman mechanism for asserting that an Orange Book-listed patent is invalid, unenforceable, or will not be infringed.
Public generic competition around XALATAN included companies such as Mylan, Apotex, Sandoz and other ANDA sponsors. The commercial result was generic entry after patent expiry rather than a sustained branded litigation strategy that preserved Pfizer’s market position.
Available public information does not establish a current, material Paragraph IV dispute affecting XALATAN. The relevant patent period has passed, and generic competition is established.
How did generic entry affect XALATAN revenue?
Generic entry produced the standard small-molecule loss-of-exclusivity pattern: rapid unit substitution, lower net price, reduced branded share, and a steep decline in the originator’s revenue contribution.
Pfizer reported XALATAN as a material product before generic entry, but later filings grouped or reduced the visibility of the product as it became a mature brand. Public company disclosures indicate that XALATAN generated roughly $1 billion or more annually around its peak period, with sales declining materially after the 2011 U.S. loss of exclusivity. Exact annual figures vary by reporting period, geography, currency, and whether the disclosure includes related products or regional sales. [3]
Financial trajectory
| Commercial phase |
Financial profile |
| 1996 to early 2000s |
Growth driven by adoption of prostaglandin therapy |
| Mid-2000s |
Mature blockbuster, supported by global brand recognition |
| 2009 to 2010 |
High revenue base before U.S. generic erosion |
| 2011 |
Major decline after U.S. generic entry |
| 2012 onward |
Residual branded revenue and international generic erosion |
| Current period |
No separately disclosed material Pfizer growth platform |
The key financial event was not a collapse in medical demand. Glaucoma prevalence and treatment demand continued. The loss was a transfer of economic value from Pfizer to generic suppliers, payers, pharmacies, and patients.
Which companies challenged or competed with XALATAN?
XALATAN competed with other prostaglandin analogues and with older glaucoma drug classes.
Branded competitors
| Product |
Active ingredient |
Company or originator |
Competitive position |
| XALATAN |
Latanoprost |
Pfizer |
Early prostaglandin leader |
| TRAVATAN / TRAVATAN Z |
Travoprost |
Alcon |
Direct prostaglandin competitor |
| LUMIGAN |
Bimatoprost |
Allergan, later AbbVie |
Direct prostaglandin competitor |
| Rescula |
Unoprostone |
Novartis |
Older prostaglandin-related product |
| Combigan |
Brimonidine/timolol |
Allergan |
Combination therapy |
| Cosopt |
Dorzolamide/timolol |
Merck, later generics |
Carbonic anhydrase inhibitor and beta blocker combination |
XALATAN’s once-daily dosing helped it establish strong prescribing momentum. Its main vulnerability was class commoditization. Once generic latanoprost became available, payers often preferred it as a low-cost first-line prostaglandin option.
Preservative-free formulations and fixed-dose combinations created separate competitive segments. These products can command higher prices when they address ocular-surface tolerability, adherence, or convenience, but they do not restore XALATAN’s expired composition patents.
What formulations are protected by XALATAN patents?
The original commercial formulation was a 0.005% latanoprost ophthalmic solution preserved with benzalkonium chloride. Patent protection around the original formulation has expired.
Formulation economics
Generic suppliers compete on:
- Sterile manufacturing capability.
- Container-closure integrity.
- Stability and cold-chain or controlled-storage requirements.
- Preservative performance.
- Bottle design and drop consistency.
- Packaging cost.
- Supply reliability.
- Contracting with wholesalers and pharmacy benefit managers.
The technical barrier is real but not exclusivity creating. Ophthalmic manufacturing requires sterile production and quality systems, yet multiple suppliers have demonstrated that these requirements are manageable. The result is a competitive market rather than a protected niche.
Preservative-free latanoprost can support differentiated pricing, but a company must rely on new formulation claims, device claims, regulatory exclusivity, or commercial differentiation. The original XALATAN patents do not block those products today.
How strong is the XALATAN patent estate?
The current patent estate is weak from an enforcement perspective because the principal patents have expired and the product has been genericized.
| Patent-strength factor |
Assessment |
| Core composition protection |
Expired |
| Method-of-use protection |
Expired |
| Orange Book blocking power |
None of material current significance |
| Formulation moat |
Low |
| Manufacturing complexity |
Moderate, but not exclusivity creating |
| Generic substitution risk |
Very high |
| Biosimilar risk |
Not applicable |
| Litigation leverage |
Low |
| Geographic protection |
Largely expired in major markets |
| Lifecycle-management value |
Limited for the original product |
The remaining value is primarily clinical familiarity, physician recognition, and distribution presence. Those factors can support residual branded demand but rarely justify premium pricing against reimbursed generics.
What generic launch scenarios exist for XALATAN?
The principal generic launch scenario has already occurred. The market now operates under mature-generic conditions.
Scenario 1: Standard generic substitution
Generic latanoprost captures most price-sensitive prescriptions. Pfizer’s branded share declines, while pharmacy substitution and payer preference reinforce generic use.
Scenario 2: Multi-source price compression
Several ANDA suppliers compete for formulary access. Wholesale prices fall, margins compress, and supply disruptions become a greater commercial risk than patent litigation.
Scenario 3: Premium formulation segmentation
Preservative-free products or delivery systems target patients with ocular-surface disease, intolerance, adherence problems, or dosing challenges. These products compete on tolerability and convenience rather than on the original XALATAN brand.
Scenario 4: Combination-product migration
Patients requiring additional pressure reduction may move to fixed-dose combinations or newer agents. This can reduce standalone latanoprost volume but does not eliminate the role of generic prostaglandin therapy.
What licensing deals affected XALATAN?
XALATAN originated with Pharmacia and became part of Pfizer through Pfizer’s acquisition of Pharmacia in 2003. The acquisition transferred commercial control, intellectual property, and development rights for Pharmacia’s ophthalmology portfolio to Pfizer. [4]
No current licensing arrangement is a material driver of XALATAN’s economics. After patent expiry, the value of licensing the original product falls sharply because generic manufacturers can enter without acquiring Pfizer’s brand rights, subject to regulatory and intellectual-property requirements.
What patent litigation affects XALATAN today?
No current patent litigation is known to create a material barrier to generic latanoprost. Historical Hatch-Waxman disputes and patent certifications mattered before the 2011 entry period. They do not provide Pfizer with current exclusivity.
The litigation profile is now more likely to involve:
- Generic manufacturing quality disputes.
- Product-liability claims.
- Labeling or advertising issues.
- Supply and distribution contracts.
- Separate patents for newer preservative-free or delivery-system products.
Those matters should not be confused with active patent protection for the original XALATAN product.
How does XALATAN compare with newer glaucoma drugs?
XALATAN remains competitive where low cost, once-daily dosing, and established efficacy drive prescribing. Newer products compete through tolerability, convenience, combination therapy, or alternative mechanisms.
| Attribute |
Generic latanoprost |
Branded newer glaucoma product |
| Price |
Low |
Usually higher |
| Evidence base |
Extensive |
Product-dependent |
| Dosing |
Often once daily |
Varies |
| Preservative-free options |
Available in selected products |
More common in differentiated products |
| Patent protection |
Expired |
May remain active |
| Payer position |
Generally favorable |
Requires differentiation |
| Main risk |
Supply and price erosion |
Patent expiry and reimbursement |
The economic center of gravity has moved from branded latanoprost to generic prostaglandin therapy and differentiated ophthalmic formulations.
What is the long-term commercial outlook for XALATAN?
XALATAN is a mature, post-exclusivity product with limited standalone growth potential. Its clinical demand is durable, but Pfizer no longer controls the economics of the latanoprost category in the way it did before generic entry.
Revenue exposure is now concentrated in residual branded prescriptions and markets where generic substitution is slower. The strongest commercial opportunities are outside the original XALATAN patent estate, including preservative-free delivery, combination products, adherence technologies, and new mechanisms for patients inadequately controlled by prostaglandin monotherapy.
For investors and licensing teams, XALATAN is primarily a reference product for generic ophthalmic economics, not an investable patent-growth asset. For generic manufacturers, the opportunity is volume and supply execution. For branded developers, the relevant opportunity is lifecycle innovation around tolerability and delivery.
Key Takeaways
- XALATAN is latanoprost ophthalmic solution 0.005%, approved by the FDA in 1996.
- Pfizer acquired the product through its 2003 acquisition of Pharmacia.
- Core U.S. patent protection expired around 2011, with related method-of-use protection extending approximately into 2012.
- Generic latanoprost entered the U.S. market in 2011.
- Pfizer’s revenue declined sharply after generic entry, following a peak-period annual revenue base of roughly $1 billion or more.
- The original XALATAN patent estate has low current strength.
- Biosimilar competition does not apply because latanoprost is a small molecule.
- Current competition centers on generic price, preservative-free formulations, fixed-dose combinations, and newer glaucoma therapies.
- No current patent dispute is known to block generic latanoprost.
- The commercial value of XALATAN lies in established clinical use, not remaining exclusivity.
FAQs
Is XALATAN still patented?
No material patent protection remains for the original XALATAN product in the United States. Its principal composition and use patents expired around 2011 to 2012.
Is generic latanoprost the same as XALATAN?
FDA-approved generic latanoprost products contain the same active ingredient and strength as XALATAN and must meet applicable equivalence requirements. Inactive ingredients, packaging, and manufacturing sites may differ.
Did Pfizer discontinue XALATAN?
Pfizer’s commercial importance for XALATAN declined after generic entry. Public financial reports no longer present the product as a major growth driver. Brand availability can vary by country and distributor.
Can a company obtain new patents on latanoprost?
A company may seek patents on a genuinely new formulation, delivery device, manufacturing process, or clinical use. It cannot restore expired patent protection for the original XALATAN formulation by repackaging the same product.
Is latanoprost still the leading glaucoma treatment?
Latanoprost remains an important first-line glaucoma therapy because of its efficacy, once-daily dosing, long clinical history, and low generic price. Its market leadership depends on the country, payer system, and availability of competing prostaglandin analogues.
References
-
U.S. Food and Drug Administration. (2017). Xalatan (latanoprost ophthalmic solution) prescribing information. FDA.
-
U.S. Patent and Trademark Office. (1994). U.S. Patent No. 5,296,504: Ophthalmic solution containing latanoprost. USPTO.
-
Pfizer Inc. (2009-2012). Annual reports and Form 10-K filings. Pfizer.
-
Pfizer Inc. (2003). Pfizer completes acquisition of Pharmacia. Pfizer corporate disclosures.
